Search Results - yu+holly+chen

2 Results

Sort By:

Using FDA-approved Small Molecule Drug Reserpine and related compounds (especially Halofantrine) To Protect Photoreceptors In Inherited Retinal Degenerations And Age-Related Macular Degeneration

Summary: The National Eye Institute seeks research co-development partners and/or licensees for a therapy using an FDA-approved small molecule drug reserpine (and related compounds especially halofantrine) that prevents photoreceptor cell death in retinal degenerations. Description of Technology: Inherited Retinal Degenerations (IRD), such as Leber...

Published: 12/20/2024 | Inventor(s): Anand Swaroop, Yu Holly Chen, Samantha Papal, Anupam Mondal, Manju Swaroop, Wei Zheng, Gregory Tawa, Wenwei Huang, Zhiji Luo

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Ear, Nose, & Throat, Collaboration Sought > Licensing

Induced Pluripotent Stem Cells Derived from Patients with CEP290-associated Ciliopathies and Unaffected Family Members

Abstract: Approximately one-third of non-syndromic retinal dystrophies involve a defect in a ciliary protein. Non-syndromic retinal ciliopathies include retinitis pigmentosa, cone dystrophy, cone-rod dystrophy, macular dystrophy, and Leber-congenital amaurosis (LCA). Many CEP290-LCA patients also exhibit auditory and olfactory defects. Induced pluripotent...

Published: 12/6/2024 | Inventor(s): Anand Swaroop, Hiroko Shimada-Ishii, Yu Holly Chen, Milton English

Keywords(s): Anosmia, Cell therapy, Ciliopathies, Congenital Blindness, Drug Development, GENE THERAPY, hearing loss, iPS, National Eye Institute, NEI, Pluripotent Stem Cells, Primary Cilia, Retina, Retinal degeneration, Swaroop, VISION

Category(s): Application > Research Materials, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Ear, Nose, & Throat, TherapeuticArea > Ophthalmology